Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cartesian Growth Corporation II (RENEU) Prices 20M Unit IPO at $10/unit
-
Analysis: Buckle up, say traders as Wall Street's wild ride shows no sign of end
-
Cartesian Growth Corporation II Announces Pricing of $200 Million Initial Public Offering
-
Cartesian Growth Corporation II Announces Pricing of $200 Million Initial Public Offering
-
Form 8-K Cantor Fitzgerald Income For: May 02
-
Form 4 Cantor Fitzgerald Income For: May 02 Filed by: LUTNICK HOWARD W
-
Cantor Fitzgerald Reiterates Overweight Rating on SeaSpine Holdings (SPNE) Following Q1 Report, Sees "Likely Share Price Appreciation"
-
Form 424B3 Cantor Fitzgerald Income
-
Sono Motors Announces Closing of Follow-on Offering
-
Sono Motors Announces Closing of Follow-on Offering
-
Pfizer (PFE) Sales Beat Estimates on Robust Covid Vaccine Sales; Analyst Weigh In on Results
-
Satellogic Announces Full Year 2021 Financial Results
-
Cantor Fitzgerald Reiterates Overweight Rating, $85 Price Target on Cutera (CUTR)
-
springbig and Tuatara Capital Acquisition Corporation Announce Amendments to Business Combination to Enhance Transaction for Public Shareholders and Additional Funding Through a Convertible Note and C
-
Form 10-K/A Cantor Fitzgerald Income For: Dec 31
-
UPDATE: Cantor Fitzgerald Downgrades Emergent BioSolutions (EBS) to Neutral
-
Sono Group (SEV) Prices 10M Share Follow-on Offering at $4/sh
-
UPDATE: Cantor Fitzgerald Starts Roivant Sciences (ROIV) at Overweight
-
Sono Motors Announces Pricing of Follow-on Offering
-
Sono Motors Announces Pricing of Follow-on Offering
-
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
-
Cantor Fitzgerald Reiterates Overweight Rating, $21 Price Target on SeaSpine Holdings (SPNE)
-
Orchid Island Capital Announces First Quarter 2022 Results
-
Cantor Fitzgerald Reiterates Overweight Rating, $12 Price Target on Lucid Diagnostics Inc (LUCD) on BeiGene's RATIONALE 306 Trial Data, "Encourage Investors to Acquire LUCD Shares at an Attractive Ent
-
SoundHound Announces Closing of Business Combination
-
Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases
-
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
Sono Group (SEV) Announces 10M Share Follow-on Offering
-
Sono Motors Announces Follow-on Offering
-
Sono Motors Announces Follow-on Offering
-
Form SC 13G Arbor Rapha Capital Bioh Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX)
-
B. Riley Securities Expands Fixed Income Division with Two Key Managing Director Hires, Ji Pak and Mary Jo Collins
-
Form N-2/A CANTOR FITZGERALD SUSTAI
-
Scynexis (SCYX) Prices $45M Stock and Warrant Offering at $3/sh
-
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
-
SeaSpine Holdings (SPNE) PT Lowered to $21 at Cantor Fitzgerald on Lower Guidance, but Analyst Reiterates "Overweight", Encourages "Investors to Acquire SPNE's Shares at Attractive Valuation"
-
Piper Sandler Expands Fixed Income Platform With Several Key Hires
-
Marinus Pharmaceuticals (MRNS) PT Raised to $28 at Cantor Fitzgerald
-
Form 424B3 Cantor Fitzgerald Income
-
Form 8-K Cantor Fitzgerald Income For: Apr 14
-
Brightwood Announces Appointment of Frederick Jelks and Chris Halajian as Directors
-
Johnson & Johnson (JNJ) Shares Dip After Revenue Miss, Suspended COVID Vaccine Sales Guidance; Results Seen as 'Mixed'
-
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
-
Orchid Island Capital Announces Estimated First Quarter 2022 Results, April 2022 Monthly Dividend and March 31, 2022 RMBS Portfolio Characteristics
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Mar 31
-
Crinetics Pharmaceuticals (CRNX) Prices 5.63M Share Offering at $22.22/sh
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering

